November 26, 2019 07:18 AM ESTUpdated 11:58 AM
R&D

Aca­di­a's sweep­ing hunt for bet­ter Nu­plazid da­ta bags mixed re­sults for schiz­o­phre­nia

Jason Mast

Editor

Five months af­ter their lead drug failed to treat schiz­o­phre­nia in a Phase III tri­al, Aca­dia is tout­ing just-bare­ly sig­nif­i­cant da­ta that sug­gest it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times